Skip to main content

Displaying 51 - 60 of 122

A Phase II, Single Arm, Open Label, Long Term Safety Rollover Trial of Oral Brigimadlin in Patients with Solid Tumors.

Miscellaneous

Miscellaneous
II
Keedy, Vicki
NCT06619509
VICCSAR24625

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Multiple Cancer Types

Miscellaneous, Phase I
I
Davis, Elizabeth
NCT03715933
VICCMDP2287


A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Thyroid

Thyroid
III
Choe, Jennifer
NCT06475989
ECOGHNEA3231

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects with Myeloid Neoplasm or in Combination with Venetoclax in Subjects with AML (AZTOUND Study)

Multiple Cancer Types

Leukemia, Myelodysplastic Syndrome, Phase I
I/II/III
Savona, Michael
NCT04256317
VICCHEMP19146

A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors.

Multiple Cancer Types

Cervical, Gynecologic, Ovarian, Prostate, Urologic, Uterine
I
Brown, Alaina
NCT06515613
VICC-DTGYN24135P


An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors

Multiple Cancer Types

Breast, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I, Uterine
I/II
Eng, Cathy
NCT06526819
VICC-DTPHI23348


A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774

Multiple Cancer Types

Miscellaneous, Phase I
I/II
Davis, Elizabeth
NCT05691491
VICCPHI10572